Phoebe Wallman

Phoebe Wallman

Auto-generated profile, based on publicly available information

Phoebe Wallman

Pharmacy Department, Maudsley Hospital, South London and Maudsley NHS Foundation Trust, London, UK

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 June 2022 in Journal of Psychopharmacology
Verified
Journal Article
Open access
TRThomas J Reilly
Thomas J Reilly
PWPhoebe Wallman
Phoebe Wallman
ICIvana Clark
Ivana Clark
CKClare-Louise Knox
Clare-Louise Knox
MCMichael C Craig
Michael C Craig
DTDavid Taylor
David Taylor
Background: Intermittent (luteal phase) dosing of selective serotonin reuptake inhibitors is one treatment strategy for premenstrual syndromes such as premenstrual dysphoric disorder. This avoids the risk of the antidepressant withdrawal syndrome associated with long-term continuous dosing. Aims: To compare intermittent dosing to continuous dosing in terms of efficacy and acceptability. Methods: We searched the Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, PsycINFO, PubMed and CINAHL for randomised trials of intermittent compared with continuous dosing of selective serotonin reuptake inhibitors in premenstrual syndromes. We extracted response rates, dropout rates and changes in symptom scores. We used random effects meta-analyses to pool study-level data and calculated odds ratio for dichotomous data and standardised mean difference for continuous data. Risk of bias was assessed using the Cochrane risk-of-bias tool. The study was registered with PROSPERO (CRD42020224176). Results: A total of 1841 references were identified, with eight studies being eligible for analysis, consisting of a total of 460 participants. All included studies provided response rates, six provided dropout rates and five provided symptom scores. There was no statistically significant differences between intermittent and continuous dosing in terms of response rate (odds ratio: 1.0, 95% confidence interval (CI): 0.23–4.31, I2 = 71%), dropout rate (odds ratio 1.26, 95% CI: 0.39–4.09, I2 = 33%) or symptom change (standardised mean difference: 0.04, 95% CI: −0.27 to 0.35, I2 = 39%). All studies had a moderate or high risk of bias. Conclusion: Since intermittent dosing avoids the potential for withdrawal symptoms, it should be considered more commonly in this patient population.


28 April 2021 in Journal of Psychopharmacology
Verified
Journal Article
Closed access
PDF file
PWPhoebe Wallman
Phoebe Wallman
ICIvana Clark
Ivana Clark
DTDavid Taylor
David Taylor
The use of antipsychotic long-acting injections (LAI) aims to reduce risk of relapse and hospitalisation in patients with schizophrenia compared with oral medication. Paliperidone palmitate is currently the only LAI that can be administered at three-monthly intervals for maintenance treatment of schizophrenia. This prospective study aimed to evaluate relapse and continuation in licensed use of paliperidone palmitate three-monthly (PP3M) over a 2-year follow-up in clinical practice. Non-interventional, observational study of patients treated in the South London and The Maudsley NHS Foundation Trust. A total of 166 patients initiated on PP3M, 55 were excluded from the study (non-F20 diagnosis (n = 43); F20 >65 years old (n = 12)). Of the 111 patients included, 67 (60%) continued PP3M for 2 years. Overall 102 patients received more than one dose of PP3M and 92 (90%) remained on the same dose of PP3M for the whole of their treatment duration. Relapse (defined as a step-up in clinical care) occurred in eight patients (7%) while on PP3M. The most common reason for discontinuation was patient refusal and the most frequent medication prescribed after discontinuation was paliperidone palmitate one-monthly (PP1M). Post hoc, we analysed outcome in those continuing any form of PPLAI (those continuing with PP3M and those switching back to PP1M). Continuation over 2 years with any PPLAI formulation was 73% (81/111) and relapse was recorded in 9% (10/111). Overall, PP3M was an effective maintenance treatment for schizophrenia after stabilisation on PP1M in a clinical setting.

26 October 2021 in European Psychiatry
Verified
Journal Article
Open access
PDF file
ICIvana Clark
Ivana Clark
PWPhoebe Wallman
Phoebe Wallman
VCVictoria Cornelius
Victoria Cornelius
DTDavid Taylor
David Taylor
Background: Paliperidone 3-monthly (PP3M) long-acting injection has proven efficacy and effectiveness in schizophrenia. Little is known of its effectiveness in other diagnoses.Methods: All patients starting PP3M were followed up for 2 years. Main outcome measures were relapse and discontinuation from PP3M.Post hocwe examined outcomes in those switched back to one monthly paliperidone (PP1M) long-acting injection.Results: Overall, 186 patients were followed-up. At the 2-year end point, 110 patients (59%) were still receiving PP3M, and 129 (70%) were receiving some form of paliperidone long-acting injection. Discontinuation from paliperidone long-acting injections (PPLAIs) was more likely with a nonschizophrenia diagnosis (hazard ratio [HR] for continuation 0.429 [95% confidence intervals (CI) – 0.21, 0.87p = 0.018)), and prior clozapine use [in PP3M patients; HR for discontinuation 1.87 [95% CI – 1.05, 3.30p = 0.032]). Relapse occurred in 20 (11%) of those receiving PP3M. Relapse on PP3M and PPLAIs was more likely in nonschizophrenia diagnosis (HR 0.17 for remaining relapse-free [95% CI – 0.06, 0.50;p = 0.001]; HR 0.21 [95% CI – 0.08, 0.58p = 0.002], respectively), polypharmacy in PP3M patients (HR for relapse 7.91 [95% CI – 3.73, 22.9;p < 0.001]) and PPLAI patients (HR for relapse 6.45 [95% CI – 2.49, 16.5;p < 0.001]), and prior clozapine use in PP3M patients (HR for relapse 6.11 [95% CI – 1.82, 20.5;p = 0.003]) and PPLAI patients (HR for relapse 4.52 (95% CI – 1.51, 13.5;p = 0.007).Conclusions: Outcomes with PP3M are excellent in practice, even when used outside its formal license. PP3M was relatively more effective in those with an F20 schizophrenia diagnosis and in those never before considered for or prescribed clozapine.

13 February 2023 in Acta Psychiatrica Scandinavica
Verified
Journal Article
Open access
Caroline CopelandCaroline Copeland
Caroline Copeland
PWPhoebe Wallman
Phoebe Wallman
DMDavid Morgan
David Morgan
EOEleanor Owen
Eleanor Owen
DTDavid Taylor
David Taylor
Background and aim: There is increasing evidence linking antipsychotic use with pneumonia, but limited evidence of an effect on pneumonia‐related outcomes such as mortality. In this study, we aimed to examine the association of pneumonia‐related death with specific antipsychotic exposure.Method: Deaths analysed were those reported to a UK‐based drug‐related deaths database, the National Programme on Substance Abuse Deaths (NPSAD), between 1997 and September 2020. We conducted a case–control study with cases defined as pneumonia‐related deaths and controls as cases with alternative causes of death. Cases were analysed by considering drugs detected at post‐mortem (PM) and by drugs prescribed to the deceased at the time of their death with calculated odds ratios (ORs) adjusted to account for confounders.Results: There were 2467 PM cases and 40,128 controls; 1818 prescribed cases and 28,018 controls. Second generation antipsychotics (SGAs) were robustly associated with an increased risk of pneumonia‐related death compared with those not prescribed or taking antipsychotics (PM detection adjusted OR [AOR] 1·34 [95% CI 1·15–1·55]; prescribed AOR 1·28 [95% CI 1·11–1·49]). First generation antipsychotics had no clear association with death from pneumonia (PM detection AOR 1·06 [95% CI 0·77–1·47]; prescribed AOR 0·91 [95% CI 0·71–1·17]). Amongst SGAs, olanzapine was associated with an increased risk of death due to pneumonia (PM detection AOR 1·49 [95% CI 1·22–1·82]; prescribed AOR 1·44 [95% CI 1·18–1·76]) as was quetiapine (PM detection AOR 1·34 [95% CI 1·07–1·66]; prescribed AOR 1·28 [95% CI 1·01–1·64]).Conclusion: Olanzapine and quetiapine were found to increase the risk of pneumonia‐related death in this NPSAD sample to a clinically important extent.

8 October 2025 in The British Journal of Psychiatry
Verified
Journal Article
Open access
PDF file
PWPhoebe Wallman
Phoebe Wallman
RGRisha Govind
Risha Govind
CCCecilia Casetta
Cecilia Casetta
EWEromona Whiskey
Eromona Whiskey
SGShreyans Gandhi
Shreyans Gandhi
DTDavid Taylor
David Taylor
Background: Clozapine remains underused despite its unparalleled efficacy in treatment-refractory schizophrenia. One of the reasons for its underuse is the fear of severe neutropenia and its consequences. Aims: To scrutinise the association between severe neutropenia and clozapine in a cohort of patients clinically diagnosed with clozapine-induced severe neutropenia. Method: We used data from the South London and Maudsley National Health Service Foundation Trust’s anonymised case register, known as the Clinical Record Interactive Search. We extracted details of cases where clozapine use was associated with two consecutive neutrophil counts below 1.5 × 109/L. A panel of clinicians independently assessed each case. Agreement was reached on which cases clozapine was the likely or definite cause of the severe neutropenia, the risk to life and whether or not rechallenge with clozapine could be attempted. Results: There were 96 cases where two consecutive neutrophil counts below 1.5 × 109/L were registered. The panel judged that 9 (9.4%) were definitely caused by clozapine and a further 11 (11.5%) were probably caused by clozapine. Overall, 18 (18.8%) patients should be precluded from ever receiving clozapine again according to the panel (all from the 20 cases where clozapine was the definite or probable cause). Of the remaining 76 cases of severe neutropenia the cause could not be determined in 60 cases, but in 11 cases the cause was benign ethnic neutropenia, in 2 others the cause was cancer chemotherapy, in 2 it was infections and in 1 it was laboratory error. In almost 80% of cases, clozapine was not the clear cause of the neutropenia observed. Conclusions: The large majority of severe neutropenia episodes mandating cessation of clozapine may not be caused by clozapine. Threshold-based monitoring systems cause unnecessary stopping of clozapine because they lack the necessary specificity for clozapine-related blood disorders.